Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems
International Journal of Molecular Sciences · 27.01.2026 · 27 (3) · 1281
DOI: 10.3390/ijms27031281 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.01.2026. Verfasst von Weronika Jóźwiak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Students Research Group, Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Łódz, Poland. Hauptthemen laut MEDLINE: Brimonidine Tartrate, Adrenergic alpha-2 Receptor Agonists, Drug Delivery Systems, Dermatologic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lodz.
Abstract (Originalsprache)
Brimonidine, a highly selective α2-adrenergic receptor agonist originally developed for glaucoma treatment, has emerged as an important dermatological agent due to its potent vasoconstrictive and anti-inflammatory properties. This review summarizes its pharmacological characteristics, and clinical applications. By activating α2-adrenergic receptors in cutaneous vessels, brimonidine induces rapid, reversible vasoconstriction and reduces neurogenic inflammation, leading to significant improvement of facial erythema in rosacea. Beyond its approved indication, topical brimonidine demonstrates efficacy in alcohol flushing syndrome, telangiectasia, post-procedural erythema, and as a local hemostatic agent in dermatologic surgery. Its favorable safety profile and minimal systemic absorption make it suitable for long-term use, though transient rebound erythema may occur. Advances in nanotechnology—such as supramolecular hydrogels and lipid-based carriers—enhance skin retention, prolong therapeutic action, and improve tolerability. These developments, together with ongoing synthesis of new quinoxaline–imidazoline analogues, open prospects for next-generation α2-agonists with optimized selectivity and dermatologic applicability. Brimonidine’s emerging role extends to dermatologic formulations for transient redness and sensitive skin management. Integrating pharmacological, formulation, and molecular insights may transform brimonidine from a niche rosacea therapy into a versatile platform for vascular, inflammatory, and aesthetic skin treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Students Research Group, Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Łódz, Poland.
- Department of Applied Pharmacy, Faculty of Pharmacy, Medical University of Lodz, Muszyńskiego 1, 90-151 Łódz, Poland.
ORCID-Profile: Weronika Jóźwiak, Magdalena Markowicz-Piasecka
Förderung
- Medical University of Lodz
Zitieren
APA
Jóźwiak, W., Pietrusiewicz, M., Piechota-Urbańska, M., & Markowicz-Piasecka, M. (2026). Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems. International Journal of Molecular Sciences, 27(3), 1281. https://doi.org/10.3390/ijms27031281
Vancouver
Jóźwiak W, Pietrusiewicz M, Piechota-Urbańska M, Markowicz-Piasecka M. Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems. International Journal of Molecular Sciences. 2026;27(3):1281. doi:10.3390/ijms27031281
BibTeX
@article{Jwiak2026,
author = {Jóźwiak, Weronika and Pietrusiewicz, Małgorzata and Piechota-Urbańska, Magdalena and Markowicz-Piasecka, Magdalena},
title = {Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {3},
pages = {1281},
doi = {10.3390/ijms27031281}
}
EUVIMED